NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
Clinical Trials
64 trialsNCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT05020236 2026-03-27
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT07043725 2026-03-27
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT05184712 2026-03-04
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso
Phase 3 Active not recruiting
NCT07424287 2026-02-20
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT06956001 2026-02-12
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06970639 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06752811 2026-02-10
pompom
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07196774 2026-01-30
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07229625 2026-01-28
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07111832 2025-12-18
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT05077215 2025-12-08
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Evergreen Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06449027 2025-10-01
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04186845 2025-09-22
Spotlight
Blue Earth Diagnostics
Phase 3 Completed
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT06079983 2025-09-12
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT07008976 2025-08-14
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT07003074 2025-06-25
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT06954246 2025-06-18
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05294172 2025-05-30
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Active not recruiting
NCT06929325 2025-04-16
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT04199689 2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06828354 2025-03-24
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT03936933 2025-02-17
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Eurofarma Laboratorios S.A.
Phase 3 Terminated
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT03511963 2024-12-31
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
Shanghai Henlius Biotech
Phase 3 Completed
NCT06754085 2024-12-31
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd.
Phase 3 Recruiting
NCT06143553 2024-11-29
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06296706 2024-11-14
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Recruiting
NCT06592326 2024-09-19
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06561607 2024-08-20
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06492941 2024-07-09
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06182592 2023-12-28
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3 Not yet recruiting
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT05755048 2023-09-01
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Unknown
NCT05110170 2023-05-16
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 3 Completed
NCT03958890 2023-04-18
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT05754853 2023-04-13
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shanghai Miracogen Inc.
Phase 3 Recruiting
NCT04241315 2023-03-23
Elucidate
On Target Laboratories, LLC
Phase 3 Completed
NCT05753865 2023-03-03
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01265849 2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3 Completed
NCT03707509 2022-07-01
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03180307 2022-02-04
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 3 Completed
NCT04889599 2022-01-11
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
Zhuhai Beihai Biotech Co., Ltd
Phase 3 Completed